These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 18414782)

  • 1. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
    De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
    Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
    García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
    Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.
    Litim N; Labrie Y; Desjardins S; Ouellette G; Plourde K; Belleau P; ; Durocher F
    Mol Oncol; 2013 Feb; 7(1):85-100. PubMed ID: 23021409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
    Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
    Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.
    Calvo JA; Fritchman B; Hernandez D; Persky NS; Johannessen CM; Piccioni F; Kelch BA; Cantor SB
    Mol Cancer Res; 2021 Jun; 19(6):1015-1025. PubMed ID: 33619228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.
    Cantor SB; Guillemette S
    Future Oncol; 2011 Feb; 7(2):253-61. PubMed ID: 21345144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.
    Barroso E; Pita G; Arias JI; Menendez P; Zamora P; Blanco M; Benitez J; Ribas G
    Breast Cancer Res Treat; 2009 Dec; 118(3):655-60. PubMed ID: 19536649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
    Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
    Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
    Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
    Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.
    Peng M; Litman R; Xie J; Sharma S; Brosh RM; Cantor SB
    EMBO J; 2007 Jul; 26(13):3238-49. PubMed ID: 17581638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACH1 Ser919Pro variant and breast cancer risk.
    Vahteristo P; Yliannala K; Tamminen A; Eerola H; Blomqvist C; Nevanlinna H
    BMC Cancer; 2006 Jan; 6():19. PubMed ID: 16430786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.